Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers identified a unique variant of alopecia areata characterized by an increase in telogen hair follicles and minimal inflammation present in the microenvironment.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study from North-East India analyzed 21 cases of frontal fibrosing alopecia, noting a high prevalence in post-menopausal women and distinct histological features such as perifollicular lymphocytic infiltrate and hydropic degeneration.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.

In this study, FAPD was characterized in a Chinese population by perifollicular mast cell infiltration, suggesting young individuals may be at higher risk than previously thought.

This study suggests that women with alopecia have decreased microcirculation oscillations, which may imply neuroinflammation as a factor in the disease's pathogenesis.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This article is a letter to the editor about fibrosing alopecia in a pattern distribution and reports no new research findings.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that dermatoscopy can quickly and non-invasively detect facial vellus hair involvement in patients with alopecia frontal fibrosante, occurring frequently and associated with specific facial lesions.

This study in Asian females found that higher use of moisturizers and sunscreen among FFA patients may reflect appearance concerns rather than indicating a direct link to the disease mechanism.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study identified a new genetic locus, ahl4, on distal Chromosome 10 that contributes to the early-onset, severe hearing loss in A/J mice compared to B6 mice.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This study found a high prevalence of beard and eyebrow alopecia in male patients with frontal fibrosing alopecia, and suggests a potential link between hormonal imbalances and the condition.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This study suggests that allergens like linalool found in personal care products may contribute to the pathobiology of frontal fibrosing alopecia by affecting immune responses and stem cell function in hair follicles.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

A new method was developed to detect pesticide residues on apples without damage.

This case report describes a 12-year-old boy with congenital insensitivity to pain with anhidrosis and progressing acro-osteolysis, highlighting the severe complications and the necessity for early intervention.

VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.

This publication presents a library of geometric medicines designed to selectively target pathogenic bacteria and fungi with high precision while minimizing ecological harm, available for free on a non-commercial basis.

This publication presents a library of precision geometric medicines that reportedly kill harmful bacteria and fungi while sparing beneficial organisms, using a delivery system that targets pathogens specifically and avoids ecological harm.

This study examined Prunus mira populations in the Qinghai-Tibetan Plateau and found high genetic diversity and substantial phylogeographic structure, suggesting geographic isolation limits gene flow; the researchers propose conservation strategies to preserve genetic resources.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.